Identification and characterisation of Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates with atypical ß-lactam susceptibility profiles using Orbitrap liquid chromatography-tandem mass spectrometry
Identification and characterisation of Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates with atypical ß-lactam susceptibility profiles using Orbitrap liquid chromatography-tandem mass spectrometry
复制标题
使用 Orbitrap 液相色谱-串联质谱法对具有非典型 β-内酰胺敏感性的肺炎克雷伯菌和铜绿假单胞菌临床分离株进行鉴定和表征
DOI:
10.1101/2022.02.27.482154
复制
发表时间:
2022
期刊:
影响因子:
--
通讯作者:
Takebayashi Y
中科院分区:
文献类型:
--
作者:
Takebayashi Y
There is significant interest in the possibility of predicting antibacterial drug susceptibility directly though the analysis of bacterial DNA or protein. We report the use ofKlebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosaandAcinetobacter baumanniitransformants to define baseline predictive rules for the β- lactam susceptibility profiles of β-lactamase positive clinical isolates. We then deployed a robust and reproducible shotgun proteomics methodology to identify β-lactamase positivity and predict β-lactam susceptibility by reference to our baseline predictive rules both in cultured bacteria and in extracts of culture-positive blood. Proteomics and whole genome sequencing then allowed us to characteriseK. pneumoniaeandP. aeruginosaisolates that differed from the expected β-lactam susceptibility profile, iteratively expanding our predictive rules. Proteomics added considerable value over and above the information generated by whole genome sequencing, allowing for gene expression, not just gene presence to be considered. Specifically, inK. pneumoniae, we identified key differences betweenacrRandramRregulatory mutations and compared the effects of OmpK36 Aspartate-Threonine or Glycine-Aspartate dipeptide porin insertions on susceptibility to cefepime and carbapenems. InP. aeruginosa, we identified differences in the gene expression effects ofmexRversusnalCmutations and related these to differences in β-lactam MICs against isolates hyper-producing AmpC β-lactamase and or producing a metallo-β-lactamase.